Biotech Values

[jbog]

Pollyvonvog,

My comment was that if it's true that Mnta is trading at these levels because of the fear of competition from Teva, that Momenta was overpriced prior to its original approval.

The Momenta approval was the most favorable outcome we could have expected with the exception that a rejection of Teva would have helped.

In hindsight, probably an outright rejection of Teva would have been more benefical than anything. In the long run, it's the poorly designed agreement that Momenta has that's hurting us at this point.